AhR activation following acute or repeated treatment with TCDD elicits NAFLD pathologies in mice that include dose-dependent hepatic lipid accumulation, immune cell infiltration, and periportal fibrosis with bile duct proliferation occurring only in males22,40–45. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.